Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...

Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and implications for molecular biology research.

Under the agreement, SanegeneBio has granted Genentech exclusive worldwide rights to develop and commercialize the undisclosed program.

PASADENA, Calif., January 20, 2026--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 5, 2026, at 4:30 p.m. ET ...

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO ® (plozasiran) for the ...

Benitec Biopharma Inc. reports 100% responder rates for BB-301 with a mid-2026 FDA meeting ahead. See why BNTC stock is upgraded to buy.

Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNSAssessment ...

Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 ...

A new legislative push to make ivermectin available without a prescription in Wyoming is drawing sharp criticism from medical ...

At the invitation of the Hon'ble Minister of Petroleum and Natural Gas of India, H.E. Shri Hardeep Singh Puri, the Hon'ble Minister of Energy and Natural Resources of Canada, H.E. Timothy Hodgson, ...

Researchers at the University of North Carolina at Chapel Hill have unveiled a platform technology designed to strengthen the potency of RNA interference therapies, a field that has promised targeted ...